Is TRT Safe? Risks, Side Effects, and What the Research Says

Testosterone replacement therapy is intended for men with hypogonadism — clinically low testosterone confirmed by blood testing, accompanied by symptoms. The Endocrine Society's clinical practice guideline recommends diagnosing hypogonadism only in men with consistent symptoms and unequivocally low morning testosterone measured on at least two separate occasions, because a single low reading can be misleading.

That diagnostic step matters for safety. The risk-benefit math of TRT is favorable for a man with a true deficiency and bothersome symptoms. It is not the same for a man with normal levels chasing a performance edge, or for a man who never got tested at all. The published safety data — including the trials cited below — were generated in men who met a hypogonadism definition, not in the general population. Applying those reassuring findings to someone with normal testosterone is not supported by the evidence.

Adults 18+ only. TRT is not appropriate for adolescents or for men who simply want to be "above average," and no legitimate provider prescribes it without labs.

For roughly a decade, the loudest safety concern about TRT was the heart. A 2014 FDA safety communication and several observational studies raised the possibility that testosterone might increase cardiovascular events, and the FDA added a caution to testosterone labeling and required manufacturers to study the question properly.

That study was TRAVERSE, published in the New England Journal of Medicine in 2023. It randomized 5,246 men aged 45-80 with hypogonadism and pre-existing or high cardiovascular risk to a testosterone gel or placebo. The headline finding: testosterone was non-inferior to placebo for the primary endpoint of major adverse cardiac events (cardiovascular death, non-fatal heart attack, or non-fatal stroke). In plain terms, in this high-risk population, testosterone did not raise the rate of those major events compared with placebo.

That is reassuring, but TRAVERSE was not an all-clear. The investigators reported higher numbers of certain events in the testosterone group, including pulmonary embolism (a blood clot in the lung), atrial fibrillation (an irregular heartbeat), and acute kidney injury. The FDA subsequently updated testosterone labeling. The practical reading: for a man with a real deficiency, the major-event heart risk appears lower than once feared, but clotting and rhythm risks are part of an honest conversation with a prescriber — especially if you have a personal or family history of clots.

Why monitoring is the point: The reason TRAVERSE's reassurance applies to monitored therapy is that it was monitored therapy. Participants were screened, dosed, and followed. Unsupervised use removes the very guardrails that make the risk profile look acceptable.

If there is one lab value every TRT patient should know, it's hematocrit — the percentage of your blood made up of red blood cells. Testosterone stimulates red-blood-cell production, and the most consistent, well-documented change across TRT studies is a rise in hematocrit, sometimes into the range called erythrocytosis (too many red cells). TRAVERSE and earlier trials both reported higher rates of erythrocytosis on testosterone than on placebo.

Why it matters: blood that is too thick is associated with a higher risk of clotting. This is why responsible providers check a complete blood count (CBC) before starting, then recheck it — commonly around 3 months, again at 6-12 months, and periodically thereafter. The Endocrine Society guideline flags a hematocrit above roughly 54% as a point to stop therapy until it normalizes, then restart at a lower dose, and to evaluate for other causes (like sleep apnea).

The fix is usually straightforward — lower the dose, change the formulation, donate blood under medical guidance, or pause — but only if someone is actually measuring it. A man self-administering testosterone with no bloodwork can develop a dangerously high hematocrit and never know until there's a problem.

This is one of the most under-discussed TRT facts: standard testosterone therapy suppresses your body's own sperm production. When you supply testosterone from outside, the brain's signaling hormones (LH and FSH) drop, and the testicles' production of both natural testosterone and sperm can shut down. The result can be a markedly lower sperm count and impaired fertility while on therapy.

For many men this effect reverses after stopping, but recovery time varies and is not guaranteed on any particular timeline. Because of this, the Endocrine Society and reproductive specialists generally advise that men who want to father children should not start standard TRT and should instead discuss alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG), which raise testosterone while preserving the body's own production. Some men also bank sperm before starting.

This is exactly the kind of decision a licensed provider exists to walk through. If fertility matters to you now or later, raise it at the very first consultation — before any prescription is written — because the right protocol may not be standard TRT at all.

The old fear that testosterone "feeds" prostate cancer came from decades-old observations and a reasonable-sounding theory. The modern evidence is more nuanced. Current research has not established that TRT causes prostate cancer; large reviews and the TRAVERSE program have not demonstrated a clear causal increase in prostate cancer with testosterone therapy in men without known disease.

That said, two facts remain firmly established and are reflected in FDA labeling and clinical guidelines: testosterone can raise PSA (prostate-specific antigen), and TRT is contraindicated in men with active prostate or breast cancer. Because of the PSA effect and the seriousness of prostate disease, providers typically obtain a baseline PSA (and consider a digital rectal exam) before starting and monitor PSA during therapy, referring to a urologist if values rise meaningfully.

So the honest framing is not "TRT is proven safe for the prostate forever" — it's "the evidence does not show TRT causes prostate cancer, it does affect PSA and is off-limits with active cancer, and that's why monitoring exists." If you have a strong family history of prostate cancer, that's a conversation to have explicitly with your provider.

Beyond the four headline concerns, TRT has a set of more routine side effects documented in FDA labeling and clinical use. None of these are reasons to panic, but they're part of an informed decision:

• Acne and oily skin — common, usually mild.
• Fluid retention — can matter for men with heart or kidney conditions.
• Breast tenderness or enlargement (gynecomastia) — related to testosterone converting to estrogen.
• Testicular shrinkage — linked to the suppression of natural production, tied to the fertility effect above.
• Worsening of sleep apnea — reported in some men.
• Mood and irritability changes — variable; some men feel better, some notice the opposite.
• Application-site or injection-specific issues — skin reactions with gels; the FDA labels topical gels with a warning about transference to women and children through skin contact, plus injection-site reactions for injectables.

The reason a structured provider relationship matters is that most of these are dose-dependent and manageable when someone is paying attention — adjusting dose, switching formulation, or addressing the specific issue.

If you read between the lines of the research, the danger isn't usually "testosterone, prescribed and monitored." It's the shortcuts. The genuinely high-risk scenarios are well understood:

• No diagnosis. Taking testosterone without confirmed, symptomatic low testosterone means you're accepting all the risks for a benefit the evidence wasn't generated to support.
• No monitoring. Skipping the CBC means a silently climbing hematocrit; skipping PSA means a missed prostate signal. The monitoring is the safety system.
• Grey-market or 'research chemical' sourcing. Testosterone bought outside the prescription system can be mislabeled, contaminated, or wrongly dosed, and you lose the clinician who'd catch a problem. We do not endorse, and this site will never point you toward, obtaining testosterone without a prescription. It's both unsafe and, for a Schedule III controlled substance, illegal.
• Ignoring contraindications. Active prostate or breast cancer, a recent cardiovascular event, untreated severe sleep apnea, a high baseline hematocrit, or an active desire to conceive are all reasons a good provider may say "not now" or "not this protocol."

This is the core reason a legitimate telehealth provider — one that requires labs, a licensed-clinician consultation, and ongoing monitoring — is the safer path than the alternatives, even when the alternatives look cheaper or faster.

Because we review TRT and men's-health telehealth providers, here's the safety checklist we apply — and that you can apply yourself. A provider worth using should:

• Require bloodwork before prescribing — at minimum total testosterone (ideally confirmed on a second draw), plus a baseline CBC/hematocrit and PSA where appropriate.
• Connect you to a licensed clinician for an actual evaluation, not a checkbox form that ends in a prescription regardless of your answers.
• Build in ongoing monitoring — follow-up labs on a defined schedule, not a one-and-done.
• Discuss fertility up front and offer or refer for alternatives (clomiphene, hCG) when appropriate.
• Be transparent about formulation and cost, and tell you whether anything is compounded.

A note on compounded medications: Some telehealth providers offer compounded testosterone or related products. Compounded medications are not FDA-approved — the FDA does not review them for safety, effectiveness, or quality the way it does brand and generic drugs. That isn't automatically disqualifying, but you should know what you're getting and why, and a good provider will explain it. Any prices you see quoted are set by the provider and change often; treat them as a starting point and verify current pricing directly at the source before you commit.

In the spirit of being straight with you: the safety findings on this page are drawn from published, citable sources — the TRAVERSE trial in The New England Journal of Medicine (2023), FDA testosterone labeling and safety communications, and the Endocrine Society's clinical practice guideline on testosterone therapy in men with hypogonadism. Those are the strongest references available, and we've framed each number as a study or label finding rather than a promise about your results.

What we cannot verify for you is any individual provider's exact current protocol, lab panel, or pricing — those change, and they're set by each provider. We also can't tell you whether TRT is right for you; that depends on labs and history only a licensed clinician can assess. And we deliberately do not cite the marketing-style efficacy figures some clinics advertise ("X% more energy") because we couldn't trace them to a controlled trial. When we can't verify a claim, we leave it out rather than repeat it.

Bottom line: Is TRT safe? For the right man — diagnosed, prescribed, and monitored — the best available evidence says the risks are manageable and the most-feared one (major heart events) was not increased in the largest trial to date. For the wrong man, or the unmonitored one, it's a real gamble. The safe version of TRT is the boring, well-monitored version.